Case Study

Study Collaboration Delivers Agility And Results During The COVID-19 Pandemic

GettyImages-1305685152 vaccine

A European multinational pharmaceutical company specializing in veterinary vaccines for more than 50 years needed extensive human vaccine experience to swiftly progress through clinical trials for its RBD dimer recombinant protein vaccine against SARS-CoV-2. To demonstrate the benefits of its BIMERVAX® vaccine in adult populations, HIPRA called on Veristat to assist with the planning and implementation of the pertinent scientific, operational, and biometrics aspects of its clinical trials, which included immunocompromised adults as part of the RBDCOV Project.

Discover how HIPRA gained support for several international studies to test efficacy, tolerability, and safety, and demonstrate the benefits of BIMERVAX®, resulting in a marketing authorization from the EMA on March 2023.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader